25.04.2012 - Even after the takeover of German-American Micromet Inc. by Amgen, Bite antibody technology remains interesting for other pharma partners.
Berlin/Martinsried – Bayer HealthCare has agreed to extend its collaboration with Amgen Research GmbH, as the former Micromet site in Munich is called today. Bayer and its partner will develop another new Bispecific T cell Engager antibody against an undisclosed target expressed in multiple tumours. The German pharma had forged a first option, collaboration and license agreement with Micromet in January 2009 to discover and develop a novel BiTE antibody targeting PSMA (prostate specific membrane antigen) for the treatment of patients with prostate cancer. Amgen acquired Micromet in March this year for US-$1.2bn and promised to keep the German site as its largest research centre outside the US. Under the terms of the present agreement, Bayer will collaborate with Amgen Research from the research phase through to the completion of Phase I clinical trials, upon which Bayer will assume full control of further development and commercialisation of the product candidate. The cooperation also includes evaluation of BiTE antibodies with an extended serum half-life. Financial details of the collaboration were not disclosed. Meanwhile, the development of the initial BiTE antibody resulting from the 2009 collaboration progresses according to plan and the initiation of the clinical Phase I trial could start as early as in the second half of 2012.
26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.
24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.
20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.
18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.
11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.
09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.